Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study

Background Inter-individual differences in treatment response are marked in multiple sclerosis (MS). This is true for Natalizumab (NTZ), to which a subset of patients displays sub-optimal treatment response. We conducted a multi-centric genome-wide association study (GWAS), with additional pathway a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology 2024-11, Vol.271 (11), p.7250-7263
Hauptverfasser:	Clarelli, Ferdinando, Corona, Andrea, Pääkkönen, Kimmo, Sorosina, Melissa, Zollo, Alen, Piehl, Fredrik, Olsson, Tomas, Stridh, Pernilla, Jagodic, Maja, Hemmer, Bernhard, Gasperi, Christiane, Harroud, Adil, Shchetynsky, Klementy, Mingione, Alessandra, Mascia, Elisabetta, Misra, Kaalindi, Giordano, Antonino, Mazzieri, Maria Laura Terzi, Priori, Alberto, Saarela, Janna, Kockum, Ingrid, Filippi, Massimo, Esposito, Federica, Boneschi, Filippo Giovanni Martinelli
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Association analysis Blood-brain barrier Female Genetic analysis Genome-wide association studies Genome-Wide Association Study Genomes Genomic analysis Germany Grb2 protein Humans Immunologic Factors - therapeutic use Italy Kallikreins Male Medicin och hälsovetenskap Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - genetics Natalizumab - therapeutic use Neurology Neuroradiology Neurosciences Original Communication Patients Pharmacogenetics Pharmacogenomics Polymorphism, Single Nucleotide Regression analysis Signal transduction Single-nucleotide polymorphism Sweden Treatment Outcome Wnt protein β-Catenin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!